{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:41:35Z","timestamp":1788489695680,"version":"build-2803163510"},"reference-count":54,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of the most vexing challenges faced by providers who care for patients after allogeneic hematopoietic cell transplantation. For the past 4 decades, research in the field has been driven by the premise that persistent graft-versus-host disease (GVHD) results from inadequate immunosuppression. Accordingly, most efforts to solve this problem have relied on retrospective or prospective studies testing agents that have direct or indirect immunosuppressive effects. Retrospective studies far outnumber prospective studies, and no controlled prospective trial has shown superior results for any agent over others. Truth be told, I do not know how to treat SR-aGVHD. Preclinical work during the past decade has provided fresh insights into the pathogenesis of acute GVHD, and translation of these insights toward development of more effective treatments for patients with SR-aGVHD has at last begun. Given the limited state of current knowledge, this \u201cHow I Treat\u201d review highlights the overriding imperative to avoid harm in caring for patients with SR-aGVHD. Prospective trials that are widely available are urgently needed to advance the field.<\/jats:p>","DOI":"10.1182\/blood.2019000960","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T13:50:16Z","timestamp":1584971416000},"page":"1630-1638","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":73,"title":["How I treat steroid-refractory acute graft-versus-host disease"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-1215","authenticated-orcid":false,"given":"Paul J.","family":"Martin","sequence":"first","affiliation":[{"name":"Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2020050711240973200_B1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2020050711240973200_B2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020050711240973200_B3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020050711240973200_B4","doi-asserted-by":"crossref","first-page":"e0183284","DOI":"10.1371\/journal.pone.0183284","article-title":"Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease","volume":"12","author":"Steinbach","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"2020050711240973200_B5","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1182\/blood-2006-05-021139","article-title":"A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease","volume":"109","author":"Hockenbery","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2020050711240973200_B6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrgastro.2017.126","article-title":"Acute graft-versus-host disease of the gut: considerations for the gastroenterologist","volume":"14","author":"Naymagon","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2020050711240973200_B7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/15258160050079470","article-title":"Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin","volume":"9","author":"McCaul","year":"2000","journal-title":"J Hematother Stem Cell Res"},{"issue":"3","key":"2020050711240973200_B8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/bbmt.2002.v8.pm11939605","article-title":"Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment","volume":"8","author":"Arai","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Pt 5","key":"2020050711240973200_B9","first-page":"1133","article-title":"Validating GSK3 as an in vivo target of lithium action","volume":"37","author":"O\u2019Brien","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"12","key":"2020050711240973200_B10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2015-10-612747","article-title":"How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver","volume":"127","author":"McDonald","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2020050711240973200_B11","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","article-title":"How I treat refractory acute GVHD","volume":"109","author":"Deeg","year":"2007","journal-title":"Blood"},{"issue":"25","key":"2020050711240973200_B12","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2020050711240973200_B13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bmt.2014.69","article-title":"Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation","volume":"49","author":"Castilla-Llorente","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2020050711240973200_bib54","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: Ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"The Oncologist"},{"key":"2020050711240973200_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial [published online ahead of print 5 March 2020]","author":"Jagasia","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2020050711240973200_B15","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.bbmt.2019.07.017","article-title":"Outcomes and predictors of response in steroid-refractory acute graft-versus-host disease: single-center results from a cohort of 203 patients","volume":"25","author":"Rashidi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020050711240973200_B16","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2020050711240973200_B17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bbmt.2013.04.018","article-title":"Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis","volume":"19","author":"Jagasia","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020050711240973200_B18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3324\/haematol.2014.108217","article-title":"Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure","volume":"99","author":"Das-Gupta","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2020050711240973200_B19","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/TP.0000000000001466","article-title":"Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on behalf of the Gruppo Italiano Trapianto di Midollo Osseo","volume":"100","author":"Malagola","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"2020050711240973200_B20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/trf.14506","article-title":"Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter?","volume":"58","author":"Worel","year":"2018","journal-title":"Transfusion"},{"issue":"1","key":"2020050711240973200_B21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41409-018-0262-x","article-title":"Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches","volume":"54","author":"Nygaard","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2020050711240973200_B22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/bmt.2013.16","article-title":"Long-term follow-up of corticosteroid refractory acute GVHD treated with an inolimomab-based algorithm: a single center experience","volume":"48","author":"Girerd","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020050711240973200_B23","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1038\/bcj.2015.33","article-title":"Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patients","volume":"5","author":"Tao","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"2020050711240973200_B24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"2020050711240973200_B25","article-title":"A phase 3 randomized study of remestemcel-L versus placebo added to second line therapy in patients with steroid refractory acute graft versus host disease [published online ahead of print 7 Sep 2019]","author":"Kebriaei","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2020050711240973200_B26","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.bbmt.2017.08.008","article-title":"Increase of intermediate monocytes in graft-versus-host disease: correlation with MDR1+Th17.1 Levels and the effect of prednisolone and 1\u03b1,25-dihydroxyvitamin D3","volume":"23","author":"Reinhardt-Heller","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020050711240973200_B27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.trim.2018.06.004","article-title":"Characterization of monocyte subtypes regarding their phenotype and development in the context of graft-versus-host disease","volume":"50","author":"Reinhardt-Heller","year":"2018","journal-title":"Transpl Immunol"},{"issue":"1","key":"2020050711240973200_B28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"Ramesh","year":"2014","journal-title":"J Exp Med"},{"key":"2020050711240973200_B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cytogfr.2016.05.002","article-title":"A gradient of glucocorticoid sensitivity among helper T cell cytokines","volume":"31","author":"Banuelos","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"2020050711240973200_B30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1189\/jlb.5A1114-532RR","article-title":"CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response","volume":"97","author":"Betts","year":"2015","journal-title":"J Leukoc Biol"},{"issue":"21","key":"2020050711240973200_B31","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/blood-2016-07-726547","article-title":"Systems analysis uncovers inflammatory Th\/Tc17-driven modules during acute GVHD in monkey and human T cells","volume":"128","author":"Furlan","year":"2016","journal-title":"Blood"},{"issue":"469","key":"2020050711240973200_B32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci Transl Med"},{"issue":"13","key":"2020050711240973200_B33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2016-09-740431","article-title":"Tissue tolerance: a distinct concept to control acute GVHD severity","volume":"129","author":"Wu","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020050711240973200_B34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.immuni.2019.06.003","article-title":"T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation","volume":"51","author":"Fu","year":"2019","journal-title":"Immunity"},{"issue":"7583","key":"2020050711240973200_B35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature16460","article-title":"Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration","volume":"528","author":"Lindemans","year":"2015","journal-title":"Nature"},{"issue":"2","key":"2020050711240973200_B36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1084\/jem.20101559","article-title":"The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells","volume":"208","author":"Takashima","year":"2011","journal-title":"J Exp Med"},{"issue":"15","key":"2020050711240973200_B37","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2016-08-732628","article-title":"Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome","volume":"129","author":"Varelias","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020050711240973200_B38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.immuni.2019.08.011","article-title":"MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota","volume":"51","author":"Koyama","year":"2019","journal-title":"Immunity"},{"issue":"5","key":"2020050711240973200_B39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrc.2018.10","article-title":"Gut microbiota injury in allogeneic haematopoietic stem cell transplantation","volume":"18","author":"Shono","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2020050711240973200_B40","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1172\/JCI125797","article-title":"The gut microbiota and graft-versus-host disease","volume":"129","author":"Fredricks","year":"2019","journal-title":"J Clin Invest"},{"issue":"16","key":"2020050711240973200_B41","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood-2016-05-717652","article-title":"Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut","volume":"128","author":"Kakihana","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020050711240973200_B42","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2016.154351","article-title":"Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease","volume":"102","author":"Spindelboeck","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"2020050711240973200_B43","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1084\/jem.20170418","article-title":"R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease","volume":"214","author":"Hayase","year":"2017","journal-title":"J Exp Med"},{"issue":"12","key":"2020050711240973200_B44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704733","article-title":"Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation","volume":"34","author":"Woywodt","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2020050711240973200_B45","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood-2011-02-334821","article-title":"Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system","volume":"118","author":"Luft","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020050711240973200_B46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbmt.2012.09.018","article-title":"Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment","volume":"19","author":"Dietrich","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020050711240973200_B47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2013.090209","article-title":"High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy","volume":"99","author":"Dietrich","year":"2014","journal-title":"Haematologica"},{"issue":"14","key":"2020050711240973200_B48","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2019000222","article-title":"A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD","volume":"3","author":"Furukawa","year":"2019","journal-title":"Blood Adv"},{"issue":"20","key":"2020050711240973200_B49","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/bloodadvances.2018020321","article-title":"Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD","volume":"2","author":"Wall","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2020050711240973200_B50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020050711240973200_B51","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am J Hematol"},{"issue":"3","key":"2020050711240973200_B52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020050711240973200_B53","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/nm.4380","article-title":"The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease","volume":"23","author":"Legoff","year":"2017","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/19\/1630\/1726868\/bloodbld2019000960c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/19\/1630\/1726868\/bloodbld2019000960c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T15:24:33Z","timestamp":1588865073000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/19\/1630\/452748\/How-I-treat-steroidrefractory-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":54,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000960","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}